FAZA PETMRI Gastro-Oesophageal Study

NCT04560036 · tracked via the Priya Life Science Canada tracker

Sponsor

University Health Network, Toronto

Phase

Not applicable

Started

2020-09-15

Last updated

2026-06-10

Condition(s) studied

Metastasized Gastro-Oesophageal Cancer

Investigational drug(s) / intervention(s)

FAZA PET/MRI scan

FAZA PET/MRI scan: FAZA PET/MRI scan before and after the standard of care chemotherapy

Study summary

This is a single arm, pilot study of PET/MRI scan with radiotracer 18F-Fluoroazomycin Arabinoside (FAZA) before and after standard of care platinum-based chemotherapy for patients with metastasized Gastro-Oesophageal Cancer.

Gastroesophageal cancer (GEC) accounted for 2,3000 deaths in Canada in 2017 and majority of the patients present or develop metastatic disease following diagnosis. These patients are treated with platinum-based chemotherapy. There is currently no biomarker that can be used to predict the therapy responses. Additionally, patients that do not respond to the chemotherapy often deteriorate rapidly and are unable to receive second line therapy. Intratumoral hypoxia (low oxygen concentration) is a signature feature of aggressive and resistant tumour phenotype. Accurately predicting hypoxia in solid tumours offers an innovative and rational pradigm for predicting therapy responses. PET/MRI is an imaging technique combining the Positron Emission Tomography (PET) scan with Magnetic Resonance Imaging (MRI) scan. A radiotracer called 18F-Fluoroazomycin Arabinoside (FAZA) is used as a type of "dye" in the PET/MRI scan.

The primary goal of the study is to validate FAZA PET/MRI as a biomarker of hyupoxia in setting of gastro-oesophageal carcinoma. Patients with GEC will undergo FAZA PET/MRI scan before and after the standard of care chemotherapy. This would be correlated with clinical outcome in patients with metastatic GEC that have different responses to chemotherapy. Ultimately, we hope that the use FAZA PET/MRI in the study can help select the most effective treatment method for advanced GEC to extend life and improve quality of life while minimizing toxicity and healthcare costs.

The study subjects' clinical management will not be changed based on the PET-MR scan within the trial.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Age ≥18 years * Patients with de novo or secondary metastasized gastro-oesophagesal cancer (adenocarcinoma) * Glomerular Filtration rate\> 45 ml/min * No allergy to contrast agents Exclusion Criteria: * Contraindication for MR as per current institutional guidelines * Inability to lie supine for at least 30 minutes * Any patient who is pregnant or breastfeeding * Any patient unable or unwilling to provide informed consent * Patients who are allergic to ethanol as the FAZA preparation contains ethanol

Primary outcome measure(s)

Validation of FAZA PET/MRI as a biomarker of hypoxia — two weeks before chemotherapy
The FAZA uptake during the first PET/MRI scan
Validation of FAZA PET/MRI as a biomarker of hypoxia — 3 months after the chemotherapy
The FAZA uptake during the 2nd PET/MRI scan

Trial sites (1)

Facility	City	Region	Status
Univeristy Health Network	Toronto	Ontario	Recruiting

More University Health Network, Toronto trials in Canada

Ted Rogers Understanding of Exacerbations in Heart Failure 2: Monitor Recruiting

Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE) Recruiting

Cabozantinib to Treat Recurrent Liver Cancer Post Transplant Recruiting

Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus Starting soon

CfDNA in Hereditary And High-risk Malignancies 2 Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04560036 on ClinicalTrials.gov ↗ ← All trials in Canada